New Biotic ALS
 
landscape-field-yellow-meadow.jpg
 

About New Biotic

New Biotic Inc is a clinical stage biotech company in microbiome research. It has researched on gut-brain science since 2008. Research and development is focused on the root causes of central nervous system (CNS) disorders, rather than just symptom management.

The company has developed a potentially game changing treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. It has obtained exciting initial pivotal human data using a microbiome formulation that could be a disease modifying therapeutic for ALS. RaphaLX™ was granted Orphan Drug Designation (ODD) by FDA. 

The company is also in discussion with the FDA about the possible use of its patent pending blood diagnostic biomarker for use in ALS as a companion diagnostic biomarker. Biomarkers for other neurological and psychiatric disorders, including Alzheimer’s, Parkinson’s, MS, schizophrenia, bipolar, etc. are currently being validated. The company holds two provisional patents in diagnostic biomarkers for CNS disorders and a few others in various stages of processing.

Having multiple products in its pipeline New Biotic welcome partners, collaborators and investors to accelerate their product rollout.

 

Management Team

Sam Ang

Chairman, C.E.O., & C.S.O.

Chairman, Chief Executive Officer, and Chief Science Officer of New Biotic Inc, a microbiome company focusing on therapeutics for CNS disorder.


He started his career as a computer scientist and Artificial Intelligence Researcher in the area of Medical Expert System. While in USC (University Southern California), he built the first medical knowledge base in 1986 for the diagnosis for all known eye diseases. In the past 20 years, Sam has been actively involved in Evidence Based Functional Medicine research for rare diseases with unknown causes, especially in the area of psychiatric and neurodegenerative diseases. His current research areas include

• Role of microbiome as a therapeutic target for ALS ( FDA Orphan Drug Designation)
•Diagnostic Biomarkers for ALS and other neurological and psychiatric conditions and early intervention.




 

Dr. William Austin Spruill

Advisory

Dr. Spruill is the Medical Director of the Roanoke Wellness Center. He received a B.A. in Psychology from UNC-Chapel Hill in 1971 and a Ph.D. in Pharmacology from UNC-Chapel Hill in 1977. In 1987 he received his M.D. from East Carolina University. After completing residency training in pediatrics at the University of Virginia, he relocated his family to Roanoke in 1990. He practiced at the Lewis Gale Clinic in Salem, VA until 2000, when he joined Physicians to Children in Roanoke, VA, where he practiced pediatrics until he retired from practice in 2013. He is an active member of the Obesity Medicine Association. He is author of Your Last Diet: A Journey to Wellness.

Dr. Spruill’s interest in family wellness arose from observing a rising incidence of weight-related disorders in children and their parents. He pursued education and training to be able offer wellness services to those families who would benefit from such services.




 

Curtis Zeng

Global Liaison Officer